+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene



Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene



Breast Cancer Research & Treatment 82(Suppl. 1): S12-S13




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035099336

Download citation: RISBibTeXText


Related references

Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells. Journal of Clinical Oncology 24(18_Suppl): 637-637, 2016

Targeting notch signaling and estrogen receptor pathways in human breast cancer stem cells. Journal of Clinical Oncology 26(15_Suppl): 22066-22066, 2016

The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers. Molecular Cancer Therapeutics 5(3): 685-692, 2006

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer 8(6): 1045-1052, 2017

Membrane-associated estrogen receptor signaling pathways in human cancers. Clinical Cancer Research 13(16): 4672-4676, 2007

Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans. Matrix Biology 35: 182-193, 2014

Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. International Journal of Cancer 109(6): 949-954, 2004

Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. Journal of Pharmacology and Experimental Therapeutics 319(3): 1124-1132, 2006

Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clinical Cancer Research 17(2): 236-246, 2011

Intersite variation of estrogen receptors in human breast cancers and response to endocrine therapy. Which section of a large tumor is the best for estrogen receptor assay?. Oncology 49(2): 89-92, 1992

Hypomethylation of the human estrogen receptor gene in primary human breast cancers. International Journal of Biological Markers 3(1): 65, 1988

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. Breast Care 8(4): 256-262, 2013

Mutational analysis of estrogen receptor-beta gene in human breast cancers. Breast Cancer Research and Treatment 78(1): 133-134, 2003

Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers. Journal of Translational Medicine 15(1): 97, 2017

Evaluation of estrogen dependency of human breast cancers 1. cytochemical study of estrogen receptor in human breast cancer tissue. Hiroshima Journal of Medical Sciences 33(2): 157-162, 1984